By Dean Seal
Shares of Aclaris Therapeutics were trading higher after the company said regulators had cleared its new drug application for a trial of ATI-052, its potential treatment for immuno-inflammatory diseases.
The stock was up 10% at $1.25 in premarket trading. Shares were trading at around this price 12 months ago.
The clinical-stage biopharmaceutical company said Tuesday that the U.S. Food and Drug Administration has cleared its investigational new drug application for a Phase 1a/1b clinical trial of ATI-052.
The trial will evaluate single and multiple ascending doses of ATI-052 and then a proof-of-concept portion in an undisclosed indication. The trial is expected to start up in the second quarter.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 22, 2025 08:06 ET (12:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.